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INTRODUCTION
The widespread use of highly active antiretrovi-
ral therapy (HAART) in developed countries has
lead to a dramatic improvement in rates of mor-
bidity and mortality for individuals with HIV-1
infection. Unfortunately, the frequent drug re-
sistance developing during HAART has proved a
major obstacle to the successful long-term man-
agement of the disease. Since 1993 primary re-
sistance to HAART has been reported in untreat-
ed patients (Erice et al., 1993; Angarano et al.,
1994) and transmission of drug-resistant viruses
has been shown to occur following infection by
different routes, including heterosexual and ho-
mosexual intercourse, intravenous drug use and
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vertically from mother to child (Bode et al., 1999;
Veenstra et al., 1995).
Current knowledge of HIV-primary resistance in-
dicates that the prevalence of transmitted resist-
ant strains has increased to substantial levels over
the past few years, with a wide variation de-
pending upon a number of factors. New infec-
tions with a virus strain already resistant to anti-
retroviral drugs, namely non-nucleoside reverse
transcriptase inhibitor (NNRTI), have a negative
impact on initial treatment response and also
shorten the time to first virologic failure (Violin
et al., 2004; Garcìa-Lerma et al., 2004; Little et al.,
2002. Borroto-Esoda et al., 2007; Pozniak et al.,
2006; Kuritzkes et al., 2008). In addition, the
emergence of resistance to non-nucleoside re-
verse transcriptase inhibitors has recently been
associated with a greater risk of negative outcome
(Hogg et al., 2006). Although it is not well known
how long mutations persist in naïve patients’ plas-
ma, several reports indicate that transmitted drug
resistant strains could persist for years as domi-
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nant quasispecies (Fox et al., 2006; Pao et al.,
2004; Delaugerre Cet et al., 2004; Barbour et al.,
2004).On the basis of these literature reports the
current guidelines (Department of Health and
Human Service guidelines for antiretroviral ther-
apy) recommend resistance testing in chronical-
ly infected persons before starting therapy. 
The aim of this study was to determine the preva-
lence of antiretroviral drug resistance by a geno-
typic test in a population with newly diagnosed
HIV-1 infection at a clinical centre in Bologna be-
tween June 2006 and September 2007.
MATERIAL AND METHODS
Population
Eighty-one drug-naïve HIV-1-infected persons
with recent diagnosis of seropositivity attending
the Infectious Diseases Unit of S. Orsola Hospital,
Bologna were recruited from June 2006 to
September 2007.
Eligibility criteria included age >18 years and an-
tiretroviral-drug-naïve status according to per-
sonal interview.
Seroconverters were defined according to the
presence of either of the following criteria:
1. a negative or indeterminate HIV antibody en-
zyme-linked immunosorbent assay result as-
sociated with a positive plasma HIV RNA re-
sult, or
2. an initially negative test for HIV antibody fol-
lowed by a positive serology result within 12
months. Primary HIV infection was confirmed
by avidity test. Each specimen was analysed in
duplicate, diluted 1:10 respectively in phos-
phate-buffered saline (PBS, reference dilution)
and 1 M Guanidine (G, test dilution). The avid-
ity index (AI) was calculated with the equa-
tion of the S/CO ratio of the test dilution
(mean of replicate) over the S/CO ratio with
the reference dilution (mean of replicate).
Peripheral blood CD4 lymphocytes
Peripheral blood CD4 lymphocytes were count-
ed by flow cytometry (FACScan, Becton &
Dickinson, Mountain View, CA) using commer-
cially available monoclonal antibody (Becton-
Dickinson) and the count of T CD4+ cells was
more than 200 cells/mm3 in all patients.
HIV-RNA viremia
Blood collected in EDTA was separated from the
cell fraction by centrifugation at 2500 rpm for
20 min and then stored at 80°C until use.
All the plasma samples were analyzed for HIV-1
RNA level using the Quantiplex HIV-RNA-3.0 as-
say (Siemens, Tarrytown, NY, USA) according to
the manufacturer’s instructions. HIV RNA levels
were expressed as copy number per ml of plas-
ma and the lowest detection limit of the assay
was 50 copies/ml. 
Genotypic analysis of plasma
Plasma viral RNA was extracted using activated
silica in a column format (QIAamp viral RNA kit;
QIAGEN, Hilden, Germany), with processing per-
formed according to the instructions provided by
the manufacturer, and resuspended in 60 µl of
RNA diluent. An aliquot of 17 µl of extracted RNA
eluate was mixed with RT-PCR reagent using the
Trugene HIV-1 Genotyping kit (Siemens). This
step amplifies the entire protease region and the
first 250 codons of reverse transcriptase as a sin-
gle amplicon. 
The cDNA product was used for the sequencing
reactions (CLIP) employing three pairs of labeled
primers that sequence the protease reading frame
(one pairs) and the beginning and the middle of
the reverse transcriptase reading frame (one pair
each). Three CLIP sequencing of the codons 4-99
of protease and codons 35-247 of RT was per-
formed in both 5 - and 3 - directions using the
Cy5 - labeled sense primers and Cy5.5-labeled an-
tisense primers. 
The forward and reverse sequences were aligned
and compared to the consensus sequence of a
lymphadenopathy-associated virus type 1 (HIV-
1LAV-1). The amino acid changes associated with
resistance to NRTIs, NNRTIs and PIs were iden-
tified using the FDA approved OpenGene DNA
Sequencing System resistance interpretation al-
gorithm, (GuideLines Rules 12.0, Siemens,
Tarrytown, NY, USA).
HIV-1 subtyping
HIV-1 subtypes were determined from HIV-1 pol
gene sequences obtained with the Trugene HIV-
1 genotyping system. Subtype assignment was
done by phylogenetic analysis using reference
strains of known subtype derived from the Los
Alamos database (www.hiv.lanl.gov). The neigh-
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bor-joining method was used to compare the se-
quences to pairwise distance matrices generated
using the Kimura 2-parameter distance estima-
tion method with a transition/transversion ratio
of 2.0.
The consistency of the phylogenetic clustering
was tested using bootstrap analysis with 100
replicates. Bootstrap values above 70 were con-
sidered sufficient for subtype assignment. CRFs
and their breakpoint locations were accurately
identified with the bootscan analysis using
SimPlot 3.5.1 software. 
RESULTS
Patients
Between June 2006 and September 2007, 81 pa-
tients were newly diagnosed with HIV-1 infection
at the S. Orsola-Malpighi Hospital of Bologna,
but only 56 (69%) met the inclusion criteria. Their
baseline demographic and clinical characteristics
are summarized in Table 1: 94.6% of the patients
were Caucasian, 91% Italian, and included 47
men and 9 women, aged 20-70 years. 
Intensive medical evaluation excluded a history of
drug abuse and transmission was established to
be by sexual contact in all subjects. 
In particular, 41 patients (73.2%) reported un-
protected homosexual relations as a risk factor
and 16 patients (28.6%) unprotected heterosexu-
al relations.
CD4 and viral load
CD4 cell count showed variable levels ranging
from 215 to 1796 (mean baseline value of
505 cells/mm3). All patients enrolled in the study
showed a moderate to high level of viral replica-
tion, ranging from 1.1x102 to >5x105 HIV-RNA
copies/ml (mean viral load 1.05x105 HIV-RNA
copies/ml). 
Phylogenetic analysis and prevalence 
of mutations correlated to drug resistance
HIV-1 RT and PR sequences derived from plas-
ma of patients analyzed showed that most (97%)
viral strains belonged to subtype B.
Among non-B, subtype A1, CRF01_AE and
CRF02_AG were detected in three patients (5.4%).
The overall weighted prevalence of patients with
primary mutations was 10.7%, (6/56) (Table 2).
The highest prevalence of resistance mutations
was observed for nucleoside reverse transcriptase
inhibitors (8.9%, 5/56) associated predominantly
with thymidine analogue mutations (TAMs) in-
cluding T215 revertants; in particular the T215D
mutation was found in four patients (7.1%, 4/56).
The weighted prevalence of patients with muta-
tions associated with resistance to non-nucleo-
side reverse transcriptase inhibitors (NNRTI) was
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TABLE 1 - Characteristics of persons newly diagnosed with HIV-1 infection in Bologna, 
June 2006-September 2007.
Patient characteristic Total number Subtype B Subtype non B
Age Median(range) 34 (20-70) 34 (20-70) 31 (23-40)
Sex Male 47 (83.9%) 45 (95.7%) 2 (4.3%)
Female 9 (16.1%) 8 (88.9%) 1 (11.1%)
Risk group Homosexual 41 (73.2%) 40 (97.6%) 1 (2.4%)
Heterosexual 15 (26.8%) 13 (86.7%) 2 (13.3%)
IVDU 0 0 0
Ethnicity Caucasian 53 (94.6%) 51 (96.2%) 2 (3.8%)
Black-African 2 (3.6%) 1 (50%) 1 (50%)
Hispanic 1 (1.8%) 1 (100%) 0
CD4 count (cells/mm3) Median (range) 505 (215-1796) 507 (215-1796) 409 (229-693)
Country of birth Italy 51 (91%) 50 (98%) 1 (2%)
other 5 (9%) 3 (60%) 2 (40%)
1.78% (1/56). The global prevalence of patients
with protease inhibitor associated mutations was
19.6% (11/56). Major mutations associated with
PI resistance were found in 1.8% (1/56) and mi-
nor mutations in 17.9% (10/56) of patients, re-
spectively.
Based on the Stanford interpretation algorithm,
among the patients with resistance mutations,
6/6 (100%) had low level NRTI resistance muta-
tions and 1/6 (16.7%) had low-level PI resistance.
Intermediate/high level resistance occurred in 2/6
(33.3%) patients for the NRTI and 1/6 (16.7%) for
the NNRTI. Lastly, 1/6 (16.7%) patients showed
dual class NRTI and NNRTI resistance.
Risk factors associated with drug resistance
mutations
All the patients with resistance mutations were
Caucasian, Italian and subtype B. There was a
trend for higher prevalence of resistance in males
(5/6, 83.3%) than females (1/6, 16.7%) and in ho-
mosexuals (5/6, 83.3%) compared with hetero-
sexuals (1/6, 16.7%). There was no association
between detection of resistance and age, CD4 and
HIV-1 viral load. There were no independent pre-
dictors of detection of resistance mutations in the
multivariable analysis.
DISCUSSION
This study determined that the prevalence of an-
tiretroviral drug resistance in an unselected pop-
ulation of HIV-1-infected individuals diagnosed
between June 2006 and September 2007 was
10.7%. This prevalence is very close to the 10.4%
rate reported in a multicentre European study of
2208 drug-naïve patients tested in 1996-2002,
which included data from 19 countries (Wensing
AMJ et al. 2005). The new data on the same co-
hort (SPREAD programme) from 1245 HIV-1-in-
fected individuals in 17 countries diagnosed in
2002-2003 reported a prevalence of 9.1%
(SPREAD Programme 2008). The prevalence of
antiretroviral drug resistance was higher (16.1%)
in a previous study of selected populations of
drug-naïve HIV-1 infected patients in Italy (the
ICoNA Cohort over the period 1996-2001) than
in our population (Violin M et al. 2004). 
As shown in table 3, the prevalence of resistance
to NRTI (8.9%) in our cohort was lower than that
observed in the ICoNA study (15.2%) and
SPREAD programme which had already detect-
ed a decrease of this prevalence from 13% (1996-
2001) to 5.4% (2002-2003). The predominance of
single thymidine-associated mutations (TAMSs)
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TABLE 2 - Characteristics of newly diagnosed with HIV-1 infection persons presenting antiretroviral 
drug resistance mutations.
Pt Age Risk Ethnicity Avidity CD4 VL Subtype RT Res. PI Res. Low Inter/high
group Index Level Level 
of Res. of Res.
M1 30 MSM C 0.40 1122 1800 B D67N, K70R, ABC AZT 3TC
K103N, M184V D4T FTC EFV
K219Q NVP DLV
M2 34 MSM C 0.50 730 120000 B T215D AZT 
D4T
M3 56 MSM C 0.55 690 86000 B A62V L210W ABC AZT D4T
T215D DDI
TDF
M4 31 MSM C 0.45 394 200000 B T215D AZT 
D4T
F5 41 HTS C 0.75 345 28000 B T215D AZT 
D4T
M6 43 MSM C 0.30 606 110000 B M46L ATZ
NFV
and 215 revertants can be explained by a combi-
nation of factors. TAMSs are selected by the
thymidine analogues (zidovudine and stavudine).
For this reason, transmission of viruses with soli-
tary TAMS most likely reflects a predominant cir-
culation of these viruses at points in time (e.g.
late 1980s and early 1990s) when there was ex-
tensive use of non-suppressive mono and dual
therapies with thymidine analogues. Introduction
of highly active antiretroviral therapy in the mid-
1990s caused a more equal distribution of resist-
ance among the three classes in patients with
treatment failure. As a result, more recent trans-
mission patterns show a relative decrease in the
proportion of NRTI resistance.
We found a higher prevalence of resistance to
NNRTI with respect to the ICoNA study, but low-
er than the European data. It is difficult to ac-
count for this finding because only one patient
in our cohort had an HIV strain with the K103N
mutation. However, as a solitary mutation may
dramatically affect the susceptibility of NNRTIs,
we support the recommendations for baseline re-
sistance testing for newly diagnosed individuals
and, if necessary, subsequent customizing of ini-
tial therapy.
The prevalence of resistance to PI was lower than
that reported in the ICoNA cohort and SPREAD
programme and this is a good result also because
the effect of single PI mutations on first-line ther-
apy is expected to be limited in the era of boost-
ed PIs because multiple mutations have to be gen-
erated before therapy fails.
With respect to the risk factors for antiretroviral
drug resistance, the multivariable analysis did not
include an independent predictor of detection of
resistance mutations. 
The prevalence of newly diagnosed patients in-
fected with non-B subtypes and circulating re-
combinant forms is very high in some European
countries (43.9% in U.K.) and is traditionally as-
sociated with immigration (Booth CL et al. 2007).
The prevalence of patients infected with non-B
subtype in our cohort was only 5.4% (one case sub-
type A1, one case CRF01_AE and one CRF02_AG)
and may be due to the poorer access to health fa-
cilities and antiretroviral therapy by immigrants.
The prevalence of homosexual males in our co-
hort was 73.2%, a higher prevalence than that
noted in the SPREAD programme (44%). Several
literature reports have demonstrated prevalences
of transmitted antiretroviral drug resistance high-
er than 20% in major US cities with large popu-
lations of homosexual men and a long period of
access to antiretroviral treatment (Grant et al.,
2003; Wensing et al., 2003; Truong et al., 2006).
For this reason, as Bologna is an Italian city with
a large entrenched homosexual population, we
expected a higher prevalence of transmission of
resistant HIV strains.
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